番茄社区app

Charles Bankhead

Charles Bankhead

Authors >

Charles Bankhead

Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. His career spans more than 30 years, including a decade with Medical World News, a leading medical trade magazine of its time. He had a long and successful freelance career before joining 番茄社区app in 2007. Charles graduated with honors from Texas Tech University, receiving a BA in journalism, and completed a master's degree in mass communication, with specialization in health communication, also at Texas Tech.

Connect:

email image

Latest from Charles Bankhead

AAO over a photo of McCormick Place in Chicago, IL.

Potentially Large Cost Savings With Home-Based OCT for Neovascular AMD

Study suggests potential to eliminate a third of in-office visits without harming care

AAO over a photo of McCormick Place in Chicago, IL.

Cataract Surgery Linked With Fewer Falls, Traumatic Injuries in Older Patients

Study adds leg and ankle fractures, intracranial hemorrhage to evidence on falls, hip fracture

AAO over a photo of McCormick Place in Chicago, IL.

Retinal Injections May Increase Risk for Cataract Surgery Complications

History of injections tied to multiple postop complications, but data open to questioning

A photo of a levonorgestrel intrauterine delivery system counseling aid.

Hormonal IUDs Linked to Increased Breast Cancer Risk

Absolute risk remains low, however

A computer rendering of prostate cancer.

Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer

Odds of undetectable PSA at 48 weeks doubled with addition of Pluvicto

A photo of a linear accelerator.

'Personalized' Approach to RT for Bladder Cancer Promising but Challenging

Low rates of toxicity and salvage cystectomy, with 2-year survival similar to surgery

inavolisib (Itovebi) over a computer rendering of advanced breast cancer.

PI3K Inhibitor Wins FDA Approval for Advanced Breast Cancer

Adding inavolisib to palbociclib/fulvestrant more than doubled PFS in endocrine-resistant disease

A computer rendering of non-small cell lung cancer.

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer

Osimertinib plus ramucirumab in first line shows 9-month PFS advantage over EGFR inhibition alone

Onco Break over a computer rendering of a cancer cell.

Let's Talk Breast Density; Cancer, Movies, and Music; Treatment-Induced Aging?

News, features, and commentary about cancer-related issues

A photo of a female dermatologist examining a man鈥檚 back with a dermatoscope.

Risk of a Second Primary Melanoma Similar Regardless of Race/Ethnicity

Differences in absolute, relative risk highlight complexities of analyzing rare events

鈥�

6

鈥�